

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12836 A1

(51) International Patent Classification⁷: **C12P 21/04**,
C12N 9/00, C07K 1/00, 14/00, A61K 35/14

(21) International Application Number: PCT/US00/22226

(22) International Filing Date: 11 August 2000 (11.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/148,907 13 August 1999 (13.08.1999) US

(71) Applicants (for all designated States except US): **FRED HUTCHINSON CANCER RESEARCH CENTER** [US/US]; Office of Technology Transfer, 1100 Fairview Avenue North, M/S: C2M 027, Seattle, WA 98109 (US). **UNIVERSITY OF WASHINGTON** [US/US]; Office of Technology Transfer, 1107 N.E. 45th Street, Suite 200, Seattle, WA 98105 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STODDARD**

WA **Barry, J.** [US/US]; 5260 116th Place S.E., Bellevue, WA 98006 (US). **PRATT, Kathleen** [US/US]; 6052 34th Avenue N.E., Seattle, WA 98115 (US). **FUJIKAWA, Kazuo** [JP/US]; 5016 Harold Place N.E., Seattle, WA 98105 (US). **DAVIE, Earl, W.** [US/US]; 9010 N.E. 22nd, Bellevue, WA 98004 (US). *WA*

(74) Agents: **KEZER, William, B.** et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th floor, San Francisco, CA 94111-3834 (US).

(81) Designated States (national): AU, CA, JP, US.


(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CRYSTAL OF A TRUNCATED PROTEIN CONSTRUCT CONTAINING A COAGULATION FACTOR VIII C2 DOMAIN IN THE PRESENCE OR ABSENCE OF A BOUND LIGAND AND METHODS OF USE THEREOF



(57) Abstract: A detailed three-dimensional structure for the C-terminal C2 domain of blood coagulation factor VIII is disclosed. The novel truncated factor VIII constructs which were designed so as to omit a significant portion of the flexible full length protein are also part of the present invention. In addition, the crystals of the protein, both in the presence and absence of bound ligands are also included. Furthermore, methods of identifying antagonists of the human factor VIII protein which can be used to inhibit coagulation or to stabilize and activate factor VIII mutants are also disclosed. Furthermore, methods of identifying variations of the C2 domain sequence and structure that can be incorporated into intact factor VIII for the purpose of administration to hemophiliac patients who are immunoreactive against wild type factor VIII are disclosed.

WO 01/12836 A1